$1.05
0.1516[16.87%]
Last update: 12:04PM Get Real Time Here
Adaptimmune Therapeutics
(NASDAQ:ADAP)Latest News for Adaptimmune Therapeutics Stock (NASDAQ:ADAP)
Adaptimmune Therapeutics Stock (NASDAQ: ADAP)
Categories: All
Friday, April 12, 2024
- Adaptimmune Therapeutics shares are trading lower after the company said it received notice of termination of the Strategic Collaboration and License Agreement with Genentech and F. Hoffman-La Roche Ltd.Benzinga Newsdesk - Apr 12, 2024, 11:45AM
- Adaptimmune Therapeutics Says On April 10, Unit Of Co, Received Notice Of Termination Of Strategic Collaboration And License Agreement With Genentech; Termination Will Become Effective 180 Days After Date Of Receipt; As Result Of Termination, Co Not Entitled To Receive Further Milestones Or Other Payments Due After Termination DateBenzinga Newsdesk - Apr 12, 2024, 8:13AM
Friday, March 08, 2024
- Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Mar 8, 2024, 1:47PM
- Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On FridayAvi Kapoor - Mar 8, 2024, 10:08AM
Wednesday, March 06, 2024
- Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS results.Benzinga Newsdesk - Mar 6, 2024, 11:49AM
- Adaptimmune Says Cash Runway Into Early 2026, With Greater Than $300M Including Current Cash On Hand, Future Expected Income From Partners And Projected Other Non-Dilutive Capital SourcesBenzinga Newsdesk - Mar 6, 2024, 7:15AM
- Adaptimmune Therapeutics Q4 EPS $(0.04) Beats $(0.10) Estimate, Sales $231.00K May Not Be Comparable To $20.47M EstimateBenzinga Newsdesk - Mar 6, 2024, 7:13AM
- Earnings Scheduled For March 6, 2024Benzinga Insights - Mar 6, 2024, 5:00AM
Tuesday, March 05, 2024
Tuesday, February 06, 2024
Wednesday, January 31, 2024
Monday, January 29, 2024
Friday, December 15, 2023
Wednesday, December 06, 2023
Wednesday, November 08, 2023
Tuesday, October 31, 2023
Tuesday, September 19, 2023
Friday, September 08, 2023
Thursday, September 07, 2023
Friday, August 25, 2023
Thursday, August 24, 2023
Thursday, August 10, 2023
- Stocks That Hit 52-Week Lows On ThursdayBenzinga Insights - Aug 10, 2023, 1:43PM
- Analyst Expectations for Adaptimmune Therapeutics's FutureBenzinga Insights - Aug 10, 2023, 8:00AM
- Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $1Benzinga Newsdesk - Aug 10, 2023, 7:20AM
- EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price TargetBenzinga Newsdesk - Aug 10, 2023, 4:47AM
Monday, August 07, 2023
Friday, July 28, 2023
Tuesday, June 06, 2023
Monday, June 05, 2023
Friday, May 26, 2023
Friday, May 12, 2023
Thursday, May 11, 2023
Monday, April 17, 2023
Tuesday, April 11, 2023
- EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price TargetBenzinga Newsdesk - Apr 11, 2023, 9:57AM
- GSK Will Return The Rights And Materials Comprised Within The PRAME and NY-ESO Cell Therapy Programs Back To Adaptimmune Therapeutics; Adaptimmune Will Receive £30M Regarding The TransitionBenzinga Newsdesk - Apr 11, 2023, 8:15AM
Wednesday, April 05, 2023
Tuesday, March 07, 2023
Monday, March 06, 2023
- Why Is TCR2 Therapeutics Stock Trading Higher Today?Ye Kuang - Mar 6, 2023, 2:01PM
- Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Mar 6, 2023, 1:25PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Mar 6, 2023, 12:31PM
- EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price TargetBenzinga Newsdesk - Mar 6, 2023, 11:17AM
- Adaptimmune Agrees To Merge With Another Cell Therapy Focused CompanyVandana Singh - Mar 6, 2023, 11:08AM
- Adaptimmune shares are trading lower after the company announced a strategic combination with TCR2 Therapeutics. The company also reported Q4 financial results.Benzinga Newsdesk - Mar 6, 2023, 8:25AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Mar 6, 2023, 8:06AM
- Adaptimmune Therapeutics Q4 EPS $(0.18) Beats $(0.25) Estimate, Sales $11.03M Beat $4.12M EstimateBenzinga Newsdesk - Mar 6, 2023, 6:47AM
- Adaptimmune Plans To Combine With TCR² Therapeutics In An All-stock Transaction To Create Preeminent Cell Therapy Company Focused On Treating Solid TumorsBenzinga Newsdesk - Mar 6, 2023, 6:04AM
- Earnings Scheduled For March 6, 2023Benzinga Insights - Mar 6, 2023, 4:52AM